Cytek Biosciences, Inc.

Cytek Biosciences, Inc. (Cytek Biosciences Division) manufactures and services advanced flow cytometry and cell analysis instrumentation, selling to federal agencies primarily as a prime contractor (99% of awards) through firm fixed-price purchase orders with no set-aside designations. The company is a for-profit organization headquartered in Fremont, California, competing in full-and-open federal procurements rather than under small-business set-asides, though two small-business set-aside awards appear in the recent footprint ($247,635 from NIAID for Aurora 4 Laser in July 2024 and $200,153 from NINDS for Aurora Evo in July 2026).

Cytek's federal work centers on two core capability streams: sale and installation of flow cytometry systems (Aurora, Aurora Evo, Northern Lights, Guava, ImageStream MKII platforms) and post-warranty preventive maintenance and repair services for those instruments. Representative prime work includes a $640,753 delivery of an Aurora Evo 67-channel system with installation and five-year service agreement to Veterans Integrated Service Network 1 (July 2026), a $734,678 purchase of an Amnis ImageStream MkII system with multi-year service to the National Heart Lung and Blood Institute (May 2023), a $676,500 five-year maintenance agreement covering six Aurora devices at the National Cancer Institute's Center for Cancer Research (April 2023), and a $498,316 Aurora Evo 67-channel system sale to the National Institute of Allergy and Infectious Diseases (July 2026). Maintenance-only contracts typically run $10,000 to $180,000 annually per instrument and often extend through option periods reaching four to five years.

Customer concentration is pronounced and NIH-dominated. NIAID accounts for 68 awards valued at $5.5 million combined potential (32% of all awards, 26% of dollars), the National Cancer Institute holds 30 awards worth $3.8 million (14% of awards, 18% of dollars), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases holds 24 awards valued at $1.4 million. The top five agencies account for 69% of recent awards and 66% of combined potential value. Within the NIH ecosystem, Cytek supplies multiple institutes and centers with instruments and maintenance covering immunological, cancer, neurological, aging, infectious disease, and dental research. The FDA (7 awards, $1.6 million) and VA (multiple VISN divisions, including significant maintenance contracts at VISN 5 and VISN 9) round out the federal footprint; USDA, USGS, CDC, Smithsonian Institution, and the Uniformed Services University represent secondary customers.

Cytek places work under two named HHS blanket purchase agreements: HHSN263201600119B (2 task orders) and HHSN263201500284B (1 task order), carrying combined potential value of $19 thousand. The overwhelming majority of awards flow through individual purchase order processes under FAR Part 13 simplified acquisition procedures rather than through vehicle task orders.

Activity has grown from 18 awards in 2022 to a peak of 43 in 2024, then declined to 21 in both 2025 and 2026 year-to-date. Nineteen awards (combined potential value $2.2 million) face ultimate completion in the next twenty-four months and therefore present recompete or renewal opportunity. The contract portfolio reflects the consumptive nature of maintenance services — most awards complete within one to five years, with many carrying option periods that extend obligation and renewal cycles.

Cytek subcontracts to a minimal degree (3 awards, 1% of footprint). Recent sub-award work includes flow cytometry products and services delivered through Triad National Security LLC on the Los Alamos National Laboratory competition management contract (June 2026), flow cytometer delivery through Roberts Oxygen Co Inc. on a health-records coordination pilot (July 2025), and flow cytometry products and services to the University of California, San Diego on a vaccine adjuvant discovery program (December 2024). Sub engagement is incidental; Cytek operates as a dominant prime in the federal biomedical instrumentation space.

By contract value and obligated spend, Cytek has materialized $19.4 million in federal obligations across 201 awards since 2015, against $21 million combined potential ceiling. The vendor's competitive posture rests on original equipment manufacturer (OEM) status — sole-source justifications and brand-name-or-equal solicitations anchor many awards to Cytek's proprietary platforms. Award velocity and dollar concentration in NIH maintenance and capital equipment procurement, combined with the upcoming recompete cliff in maintenance renewals, position Cytek as entrenched in the federal life-sciences instrumentation supply chain, with limited exposure to competitive team scenarios or sub-tiers.